Previous 10 | Next 10 |
Seasoned financial executive strengthens management team REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnes...
Purple Biotech press release ( NASDAQ: PPBT ): Q2 GAAP EPS of $0.61. Research and Development Expenses were $2 million, same as to $2 million in the same period of 2021. Selling, General and Administrative Expenses were $1.5 million, same as to $1.5 million in the same...
REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune...
Purple Biotech ( NASDAQ: PPBT ) announced that following the decision by former CEO Isaac Israel to step down from his CEO role and reduce the scope of his engagement with the Company for personal reasons, effective July 10, 2022, Gil Efron, will assume the CEO role....
Gil Efron appointed as Chief Executive Officer Isaac Israel to transition to advisor role, continue as Board member REHOVOT, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focus...
Purple Biotech (NASDAQ:PPBT) reported interim data from a phase 1 trial of NT219 as a standalone therapy to treat adults with advanced solid tumors. The study included patients with colorectal, pancreatic and breast cancers and also gastroesophageal junction (GEJ), esophageal and appendi...
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer REHOVOT, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage...
Gainers: Celularity CELU +10%. Purple Biotech (PPBT) +8%. BioSig Technologies (BSGM) +4%. Concert Pharmaceuticals (CNCE) +4%. Molecular Partners (MOLN) +4%. Losers: Baudax Bio BXRX -28%. Doximity DOCS -9%. Radius Health (RDUS) -7%. N...
Purple Biotech (NASDAQ:PPBT) on Wednesday initiated the phase 2 portion of its ongoing study of monoclonal antibody CM24, which has the potential to treat multiple cancers. The mid-stage portion of the study will evaluate the safety and tolerability of CM24 in combination with Bristol Myers S...
REHOVOT, Israel, May 18, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcom...
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its ...
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...